Literature DB >> 23997529

Recurrent orbital space-occupying lesions: a clinicopathologic study of 253 cases.

Weiqiang Tang1, Yan Hei, Lihua Xiao.   

Abstract

OBJECTIVE: To analyze the clinical features, histopathologic classification and frequencies of various types of recurrent orbital space-occupying lesions.
METHODS: A retrospective study was carried out in 253 consecutive patients with recurrent orbital space-occupying lesions treated by surgical excision in the Institute of Orbital Diseases, the General Hospital of the Armed Police Force from January 2009 to December 2010.
RESULTS: The patients included 123 males and 130 females aged 2 to 78 years (mean, 36.2 years), and the last recurrence interval after operation ranged from 1 month to 40 years (median, 4.75 years). Of all the cases, 159 (62.8%), 65 (25.7%), 20 (7.9%), 8 (3.2%) and 1 (0.4%) had previously experienced once, twice, three, four and six times of surgeries, respectively. Among them, 29 (11.5%) cases had recurred 3 times or over, and 37 (14.6%) cases got recurrence in 10 or more years postoperatively. Most of the patients with local recurrence presented with various clinical manifestations, while 31 (12.3%) cases were symptom-free. Two hundred and thirty-one (91.3%) cases underwent surgical removal of the recurrent orbital lesions, and another 22 (8.7%) cases had to receive the exenteration of orbit. Categories of these recurrent orbital lesions after operation were as follows: lacrimal gland tumors, 65 (25.7%) cases; vasogenic diseases, 54 (21.3%) cases; neurogenic tumors, 42 (16.6%) cases; secondary tumors, 24 (9.5%) cases; orbital inflammation, 21 (8.3%) cases; myogenic tumors, 14 (5.5%) cases; fibrous and adipose tumors, 12 (4.7%) cases; lympho-hematopoietic tumors, 7 (2.8%) cases; bone or cartilage tumors, 7 (2.8%) cases; orbital cysts, 6 (2.4%) cases; and indefinitely differentiated tumor, 1 (0.4%) case. The 10 top histopathologic diagnoses were lacrimal gland pleomorphic adenoma, hemangiolymphangioma, lacrimal gland adenoid cystic carcinoma, meningioma, inflammatory pseudotumor, neurofibroma, sebaceous gland carcinoma, vascular malformation, rhabdomyosarcoma and hemangioma.
CONCLUSIONS: The variety of recurrent orbital lesions after operation includes mainly of tumors except for vascular malformation and orbital inflammatory lesions. The lacrimal gland epithelial tumor is most prone to relapse after resection, and early and longer-term postoperative follow-up is needed.

Entities:  

Keywords:  Orbital space-occupying lesions; lacrimal gland epithelial tumor; orbital inflammatory lesions; recurrence; vascular malformation

Year:  2013        PMID: 23997529      PMCID: PMC3752348          DOI: 10.3978/j.issn.1000-9604.2013.08.04

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  27 in total

Review 1.  Orbital rhabdomyosarcoma.

Authors:  Zeynel A Karcioglu; Doris Hadjistilianou; Marta Rozans; Sonia DeFrancesco
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

2.  Images in clinical medicine. Orbital and cerebral arteriovenous malformations.

Authors:  Omar Choudhri; Steven Daniel Chang
Journal:  N Engl J Med       Date:  2011-09-29       Impact factor: 91.245

3.  Sphenoorbital meningioma: surgical technique and outcome.

Authors:  Soichi Oya; Burak Sade; Joung H Lee
Journal:  J Neurosurg       Date:  2010-12-24       Impact factor: 5.115

4.  Intraorbital meningiomas: a pathologic review using current World Health Organization criteria.

Authors:  Deepali Jain; Katayoon B Ebrahimi; Neil R Miller; Charles G Eberhart
Journal:  Arch Pathol Lab Med       Date:  2010-05       Impact factor: 5.534

5.  Recurrent lacrimal gland pleomorphic adenoma: clinical and computed tomography features.

Authors:  Alan A McNab; Khami Satchi
Journal:  Ophthalmology       Date:  2011-10       Impact factor: 12.079

Review 6.  [Clinical and neuroradiological diagnostics of orbital tumors].

Authors:  C M Poloschek; W A Lagrèze; G J Ridder; C Hader
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

7.  [Orbitotemporal facial involvement in type 1 neurofibromatosis (NF1)].

Authors:  B Rilliet; B Pittet; D Montandon; A-P Narata; S de Ribaupierre; F Schils; D Boscherini; C Di Rocco; N Ducrey
Journal:  Neurochirurgie       Date:  2010-03-19       Impact factor: 1.553

8.  Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1.

Authors:  Jerry A Shields; Carol L Shields; Richard Scartozzi
Journal:  Ophthalmology       Date:  2004-05       Impact factor: 12.079

9.  [Removal and plastic reconstructive surgery of orbital neurofibroma].

Authors:  Xian-Qun Fan; Ming Lin; Jin Li; Hui-Fang Zhou; Yao Fu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-12-11

10.  Case series on vascular malformation and their review with regard to terminology and categorization.

Authors:  Devi Charan Shetty; Aadithya B Urs; Harish Chandra Rai; Nitin Ahuja; Adesh Manchanda
Journal:  Contemp Clin Dent       Date:  2010-10
View more
  4 in total

1.  Surgical resection of invasive adenoid cystic carcinoma of the lacrimal gland and wound closure using a vertical rectus abdominis myocutaneous free flap.

Authors:  João Paulo Andrade; Sergio Figueiredo; Julio Matias; Ana Catarina Almeida
Journal:  BMJ Case Rep       Date:  2016-09-19

2.  Sarcomatous Carcinoma of the Orbit: A Case Report and Review of the Literature.

Authors:  Ninan Mathew; Mathen Mathew; Jon Farrah
Journal:  Case Rep Ophthalmol       Date:  2015-06-10

3.  Proptosis Revealing a Rare Lacrimal Gland Tumor: A Case of Chondroid Syringoma in a 35-year-old Patient.

Authors:  Boubacar Efared; Kadre Ousmane Kadre Alio; Boubacar Idrissa; Aïchatou Balaraba Abani Bako; Habiba Salifou Boureima; Ali Salèye; Nouhou Hassan
Journal:  Clin Pathol       Date:  2022-01-09

4.  Adult Orbital Lesions in Saudi Arabia: A Multi-centered Demographic Study with Clinicopathological Correlation.

Authors:  Abrar K Alsalamah; Azza My Maktabi; Hind M Alkatan
Journal:  J Epidemiol Glob Health       Date:  2020-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.